Company Announcements

Form 8.3 - Willis Towers Watson plc

Source: RNS
RNS Number : 1548V
Societe Generale SA
12 April 2021
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

               Willis Towers Watson plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.000304635 ordinary shares

Date of dealing

09/04/2021

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

883,683

0.69

1,238

0.00

(2) Derivatives (other than options)

1,136

0.00

587,906

0.46

(3) Options and agreements to purchase/sell

0

0.00

0

0.00

Total

*1,768,305

*1.37

589,144

0.46

                               

* Include the holding of shares 883,486 on borrow products

 

               

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

16

237.66

Purchase

100

238.38

Purchase

100

239.59

Purchase

38

237.66

Purchase

193

237.66

Purchase

76

237.66

Purchase

38

237.66

Purchase

192

239.98

Purchase

9

238.81

Purchase

9

239.52

Purchase

10

239.6

Purchase

10

239.52

Purchase

1

239.142

Purchase

1

237.662

Purchase

1

239.042

Purchase

1

237.902

Purchase

1

239.242

Purchase

1

239.102

Purchase

1

238.382

Purchase

1

239.652

Purchase

1

239.592

Purchase

1

237.302

Purchase

1

239.612

Purchase

1

238.122

Purchase

1

239.322

Purchase

1

239.612

Purchase

1

238.612

Purchase

1

239.162

Purchase

1

237.662

Purchase

1

238.782

Purchase

1

238.822

Purchase

1

237.072

Purchase

1

238.922

Purchase

1

238.402

Purchase

1

238.822

Purchase

1

237.992

Purchase

1

238.382

Purchase

1

239.092

Purchase

1

238.092

Purchase

1

239.032

Purchase

1

238.782

Purchase

1

236.822

Purchase

1

239.362

Purchase

1

238.872

Purchase

1

239.352

Purchase

836

239.98

Purchase

684

239.98

Sale

100

238.54

Sale

74

239.08

Sale

26

239.08

Sale

1,130

239.98

Sale

100

238.39

Sale

40

238.79

Sale

40

238.79

Sale

20

238.79

Total Purchases

2,344

 

Total Sales

1,530

 

 

Derivatives transactions (other than options transactions)

 

Product name,
e.g. CFD

Nature of transaction
(Note 6)

Number of relevant securities
(Note 7)

Price per unit USD
(Note 5)

Euro Medium Term Note

Increased long

1

112.5737

 

(b)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any 

other person relating to the voting rights of any relevant securities under any option referred to on this 

form or relating to the voting rights or future acquisition or disposal of any relevant securities to which 

any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            No

 

Date of disclosure

12/04/2021

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEFLFLISAIFLIL